Abstract
Role of clinical laboratories in response to the COVID-19 pandemic.
Highlights
Absence of adequate testing due to various factors, most significant of which being supply chain issues, is most likely contributing to community spread
Emergency Use Authorization (EUA) are accompanied by recommendations of the ideal test protocol, laboratories have to increase COVID-19 test output without compromising on accuracy yet with less than ideal variables
The pre-analytical constraints emerged as the viral transport media used for collecting nasopharyngeal (NSP) swab samples became exhausted, forcing laboratories to hold up sample collection, or revert to other collection methods
Summary
Absence of adequate testing due to various factors, most significant of which being supply chain issues, is most likely contributing to community spread. In response to the outbreak, several state authorities and commercial companies have developed diagnostic assays to test individuals for the SARS-CoV-2 infection. Over 40 diagnostic assays have received Emergency Use Authorization (EUA) from the Federal US FDA for COVID-19 testing.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
